Overview Pembrolizumab (Keytruda): CADTH Reimbursement Advice: Sign: Together with chemotherapy, to the treatment of adult people with locally recurrent unresectable or metastatic triple-destructive breast cancer who may have not obtained prior chemotherapy for metastatic ailment and whose tumours express programmed cell Demise-ligand one (mixed favourable score ≥ ten) as determined https://aleisterg701dfh5.bligblogging.com/profile